Amlogen - Company Profile

Developer of gene therapy for Alzheimer's disease. This company develops a novel gene therapy strategy to reduce amyloid accumulation in the brain. Their approach focuses on increasing levels of the PPCA enzyme in the brain via AAV gene therapy, which has shown promise in reducing amyloid plaque accumulation in preclinical models. The therapy aims to address the underlying cause of amyloid accumulation by enhancing the lysosomal system's ability to clear amyloid proteins, thereby preventing or reducing the progression of Alzheimer's disease and other related neurodegenerative diseases. The research leverages insights into the parallels between Alzheimer's and lysosomal storage diseases.